Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis HN019 + oligosaccharides
- Development stage
- Preclinical
- Lead developer
- DuPont
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis HN019 + oligosaccharides is an investigational synbiotic combination. It combines the probiotic strain *Bifidobacterium animalis* subsp. *lactis* HN019 (also known as Bifidus DR10) with prebiotic oligosaccharides. [1, 5, 8] This combination was evaluated by the Johns Hopkins Bloomberg School of Public Health in a clinical trial where it was used to fortify milk for children aged 13-36 months. The study aimed to determine its effectiveness in preventing diarrhea and pneumonia, as well as improving growth and development. [Context] The probiotic component, DR10, was developed by the New Zealand dairy co-operative Fonterra and has been shown to support gut and immune health. [3, 4, 7] Synbiotics work by providing beneficial microorganisms (probiotics) and a substrate (prebiotics) that promotes their growth and activity within the host's gut.
- Brand names
- Bifidus DR10HOWARU BifidoProbio DR10
- Other names
- prebiotic + probiotic-Johns Hopkins Bloomberg School of Public HealthBifidus DR10/oligosaccharidesBifidobacterium lactis DR10 + oligosaccharides
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis HN019 + oligosaccharides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis HN019 + oligosaccharides.